Detalhe da pesquisa
1.
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Clin Drug Investig;
41(2): 133-147, 2021 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33527237
2.
Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
J Clin Pharmacol;
58(5): 666-673, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29329497
3.
Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase.
J Med Chem;
50(19): 4642-7, 2007 Sep 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17718551
4.
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325.
ChemMedChem;
10(4): 727-35, 2015 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25759009
5.
Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
ChemMedChem;
8(12): 1930-40, 2013 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24127258
6.
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.
ACS Med Chem Lett;
3(4): 332-6, 2012 Apr 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24900473
7.
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.
ACS Med Chem Lett;
2(3): 207-12, 2011 Mar 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24900304
8.
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
J Med Chem;
53(6): 2443-63, 2010 Mar 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20163176